3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NIH
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Leukemia, Myeloid, Acute
3
Head and Neck Neoplasms
3
Lymphoma, T-Cell, Peripheral
2
Lymphoma
2
Thyroid Neoplasms
1
Pancreatic Neoplasms
1
NSCLC
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Hereditary Sensory and Autonomic Neuropathies
1
Breast Neoplasms
1
Advanced Solid Tumor
1
Interventions
Azacitidine
33
venetoclax
10
decitabine and cedazuridine drug combination
7
Decitabine
7
sabatolimab
3
pevonedistat
3
cedazuridine
3
ON 01910
3
spartalizumab
2
glasdegib
2
cc-486
2
Panobinostat
2
Cytarabine
2
BI 6727
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
zanubrutinib
1
triciribine
1
tipifarnib
1
terameprocol
1
tapotoclax
1
tagraxofusp
1
ruxolitinib
1
orludodstat
1
navitoclax
1
lonafarnib
1
lintuzumab
1
lenzilumab
1
guadecitabine
1
exatecan
1
bisantrene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Myelomonocytic, Chronic
×
tipifarnib
×
Clear all
NCT02807272
2024-07-17
CMML/AML
Kura Oncology, Inc.
Phase 2
Completed
44 enrolled
17 charts